Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

Local health boards invited adults aged 75–79, including those turning 75 before July 2025, to come forward for their free RSV vaccine ahead of the winter. By the end of November 2024 ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study. The phase 3 randomized controlled ...

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 years and older.

On the flip side, vaccines Prevnar and Abrysvo underperformed expectations. RSV vaccine Abrysvo specifically floundered in the fourth quarter. The product's sales fell 62% year over year to $198 ...

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for ...

The CDC encourages doctors to vaccinate babies and adults over 60 years old, with two RSV vaccines for seniors, GSK’s Arexvy (88% effective) and Pfizer’s Abrysvo(85% effective), currently ...

Older people across Oxfordshire are being invited to receive their respiratory syncytial virus (RSV) vaccine. The invitations are being sent out to residents in Buckinghamshire, Oxfordshire, and ...

The winter respiratory virus season is still in full swing, with Illinois under a "high" alert level from the Centers for Disease Control and Prevention. Among the viruses circulating most are ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once again. GSK now expects to generate more than 40 billion pound ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...